Evidence map›Paper›PMID 27311985›Full record

ArticleBiochemical pharmacology2016

MicroRNA hsa-miR-25-3p suppresses the expression and drug induction of CYP2B6 in human hepatocytes.

Yaqiong Jin, Dianke Yu, William H Tolleson, Bridgett Knox, Yong Wang, Si Chen, Zhen Ren, Helen Deng, Yongli Guo, Baitang Ning

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemical pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Novel Approaches to Characterize Individual Drug Metabolism and Advance Precision Medicine.Drug metabolism and disposition: the biological fate of chemicals · 2023
    Review
  3. Review
  4. Review
  5. Role and Regulation of Hepatobiliary ATP-Binding Cassette Transporters during Chemical-Induced Liver Injury.Drug metabolism and disposition: the biological fate of chemicals · 2022
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. miR-15a-3p Protects Against Isoniazid-Induced Liver InjuryFrontiers in molecular biosciences · 2021
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. A feature-based analysis identifies COL1A2 as a regulator in pancreatic cancer.Journal of enzyme inhibition and medicinal chemistry · 2019
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Yaqiong JinBeijing Key Laboratory for Pediatric Diseases of Otolaryngology, Head and Neck Surgery, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China.
Dianke YuNational Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA. Electronic address: dianke.yu@fda.hhs.gov.
William H TollesonNational Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA.
Bridgett KnoxNational Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA.
Yong WangNational Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA.
Si ChenNational Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA.
Zhen RenNational Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA.
Helen DengArkansas Department of Health, Little Rock, AR 72205, USA.
Yongli GuoBeijing Key Laboratory for Pediatric Diseases of Otolaryngology, Head and Neck Surgery, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China. Electronic address: guoyongli@bch.com.cn.
Baitang NingNational Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA. Electronic address: baitang.ning@fda.hhs.gov.
National Center for Toxicological Research · USUnited States Food and Drug Administration · USArkansas Department of Health · USBeijing Children’s Hospital · CNCapital Medical University · CN

Funding

Intramural FDA HHS FD999999
6 · The paper itself

Abstract

Cytochrome P450 2B6 (CYP2B6), mainly expressed in the liver and brain, is important for processing a number of widely used drugs. Variations in CYP2B6 expression are associated with decreased drug efficacy or adverse effects in some patients. Although CYP2B6 genetic variants are associated with its differential expression, epigenetic mechanisms affecting CYP2B6 gene regulation have not been established. Sequence analysis identified 29 domains in the CYP2B6 mRNA transcript that could be subject to regulation by microRNAs. Inverse correlations were found in human hepatocytes for the levels of the microRNAs hsa-miR-504-5p and hsa-miR-25-3p compared with CYP2B6 mRNA. Reporter gene assays showed that hsa-miR-25-3p suppresses CYP2B6 expression by targeting a specific sequence in the 3'-untranslated region of the mRNA transcript. Electrophoretic mobility shift assays confirmed that hsa-miR-25-3p forms stable complexes with its cognate mRNA sequence and that it recruits cellular factors, including Ago-4. Transfection of HepaRG cells with hsa-miR-25-3p mimics inhibited expression of the endogenous CYP2B6 gene and it also decreased rifampicin-dependent induction of CYP2B6 at the mRNA and protein levels. In summary, in silico and in vitro analyses show that hsa-miR-25-3p suppresses CYP2B6 expression in human liver cells via an epigenetic mechanism.

Indexed as

Epigenesis, GeneticGene Expression Regulation, EnzymologicBinding SitesCell Culture TechniquesCell Line, TumorCytochrome P-450 CYP2B6Cytochrome P-450 CYP2B6 InhibitorsElectrophoretic Mobility Shift AssayHepatocytesHumansLiverMicroRNAsRifampinRNA, MessengerCYP2B6 protein, humanCytochrome P-450 CYP2B6Cytochrome P-450 CYP2B6 InhibitorsMicroRNAsMIRN25 microRNA, humanRifampinRNA, MessengerCYP2B6Drug metabolizing enzymeshsa-miR-25-3pInter-individual variabilityPharmacogenomics

Identifiers

PMID27311985
PMCPMC5672627
OpenAlexW2426080411

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.